Evaluation of a protocol for immunomodulatory treatment of patients with rheumatoid arthritis who are cancer survivors
Keywords:
Rheumatoid Arthritis, Protocol, Cancer, PatientsAbstract
Introduction: Rheumatoid arthritis is a systemic autoimmune disease that predominantly affects the diarthrodial joints and is frequently accompanied by systemic manifestations. Survival in patients with rheumatoid arthritis who present with cancer is currently a controversial topic. Given the advancement of oncospecific treatment, it is now possible to speak of patients with rheumatoid arthritis who are cancer survivors. Adequate follow- up and treatment promote a better quality of life.
Objective: To evaluate the effectiveness of an immunomodulatory treatment protocol for patients with rheumatoid arthritis who are cancer survivors in the province of Holguín, Cuba.
Materials and methods: A pre-experimental developmental study was conducted using a purposive, non-probability sample of 100 cancer survivors from the province of Holguín, Cuba. The methods used were observation, analysis, synthesis, induction, deduction, the systems approach, and Fisher's test.
Results: A protocol for immunomodulatory treatment is proposed for patients with rheumatoid arthritis who are cancer survivors in the province of Holguín, Cuba. This protocol utilizes generative artificial intelligence and natural medicine as a novel approach. The results obtained before and after its application are presented.
Conclusions: Patients in the 51 age group were predominant, and women were female. The most prevalent risk factors were a personal history of hypertension, and smoking. It is demonstrated that the implementation of a protocol contributes to improving the quality of life of patients with rheumatoid arthritis who are cancer survivors.
Downloads
References
1. Singh N, Grivas P, Makris UE, Suarez Almazor ME, O’Hare AM, Barton JL. Use of disease-modifying antirheumatic drugs in rheumatoid arthritis: supporting shared decision-making between patients with cancer and clinicians. ACR Open Rheumatol.2023[citado 13/10/2025];5(6):305-307. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10267802/
2. Bin Joo Y, Min Jeong S,Park YJ, Kim KJ,Park KS. Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients. J Rheum Dis. 2022[citado 19/09/2025];29(3):162-170. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10324922/
3. Pundole X, Zamora NV , Siddhanamatha H, Lin H, Tayar J,Hong Leung C , et al. Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clin Rheumatol.2020[citado 06/10/2025]; 39(10):2943-2950. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10556973/
4. McCarter KR, Wolfgang T, Arabelovic S, Wang X,Yoshida K, Banasiak EP, et al. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023[citado 07/09/2024];5(5):e274-e283. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10571093/
5. Wetzman A, Lukas C, Gaujoux Viala C, Mamtani R, Barnetche T, Combe B, et al. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2023[citado 07/09/2024];75(2):260-271. Disponible en: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24784
6. Cunningham Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, et al. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Arthritis Rheumatol. 2022[citado 06/08/2025];74(3):527-540. Disponible en: https://acrjournals.onlinelibrary.wiley.com/toc/23265205/2022/74/3?page=2
7. Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol. 2020[citado 06/12/2025];32(3):315-320. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7212600/
8. Shimizu T, Kawashiri SY, Morimoto S, Kawazoe Y, Kuroda S, Kawasaki R, et al. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. Trials. 2023 [citado 30/08/2025];24(1):161. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9985291/
9. Centro Nacional Coordinador de Ensayos Clínicos (CENCEC). Jusvinza in adult patients with rheumatoid arthritis from Camagüey and Eastern provinces: Phase III trial [RPCEC00000433]. Registro Público Cubano de Ensayos Clínicos. 2023 [citado 26/06/2025]. Disponible en: https://rpcec.sld.cu/trials/RPCEC00000433-En/revisions/5954/view
10. Peláez O. Avanza ensayo clínico Fase III del fármaco Jusvinza para la artritis reumatoide.Granma. 10/06/2025;Cuba. Disponible en: https://www.granma.cu/cuba/2025-06-10/avanza-ensayo-clinico-fase-iii-del-farmaco-jusvinza-para-el-tratamiento-de-la-artritis-reumatoide-10-06-2025-23-06-11
11. Lopez Olivo MA, Colmegna I, Karpes Matusevich AR, Ruyu Qi S, Zamora NV, Sharma R, et al. Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. Arthritis Care Res (Hoboken). 2020[citado 30/08/2025];72(3):309-318.Disponible en: https://acrjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/acr.23865
12. Hernández Sampieri R, Fernández Collado C, Baptista Lucio MP. Metodología de la investigación. 5a ed. México: McGRAW-HILL / Interamericana Editores, S.A. de C.V; 2010 [citado 17/07/2020]. Disponible en: https://libros.uclv.edu.cu/book/699
13. Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023 [citado 26/06/2025];75(1):15-22. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10092655/
14. Berghea F, Andras D, Berghea EC. Generative Artificial Intelligence and Risk Appetite in
Medical Decisions in Rheumatoid Arthritis. Appl Sci. 2025 [citado 06/07/2025];15(10):5700. Disponible en: https://www.mdpi.com/2076-3417/15/10/5700
15. Krusche M, Callhoff J, Knitza J, Ruffer N. Diagnostic accuracy of a large language model in rheumatology: comparison of physician and ChatGPT-4. Rheumatol Int. 2023 [citado 13/08/2025];44(2):303-3066. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10796566/
16. McCarter KR, Wolfgang T, Arabelovic S, Wang X, Yoshida K, Banasiak EP, et al. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023 [citado 06/04/2025];5(5):e274-283. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10571093/
17. Shimizu T, Kawashiri SY, Morimoto S, Kawazoe Y, Kuroda S, Kawasaki R, et al. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. Trials. 2023[citado 06/10/2024];24(1):161. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9985291/
18. Asociación Médica Mundial. Declaración de Helsinki de la AMM. Principios éticos para las investigaciones médicas en seres humanos. Fortaleza, Brasil: Asociación Médica Mundial; 2013. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
19. Ministerio de Salud Pública de Cuba. Guías de práctica clínica para el diagnóstico y tratamiento de la artritis reumatoide. La Habana: MINSAP; 2018. Disponible en: http://www.sld.cu/guias-clinicas
20. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 [citado 02/10/2025];73(7):924-939. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9273041/
21. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019 [citado 11/11/2025];71(10):1599-1613. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC6764882/
22. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 [citado 19/08/2025];82(1):3-18. Disponible en: https://ard.eular.org/article/S0003-4967(24)08619-9/fulltext
23. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023[citado 06/08/2025];82(1):19-34. Disponible en: https://ard.eular.org/article/S0003-4967(24)08620-5/fulltext
24. Massardo L, Suárez Almazor ME, Cardiel MH, Nava A, Levy RA, Laurindo I, et al. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano de Estudio de Artritis Reumatoide. J Clin Rheumatol.2009[citado 09/01/2026];15(4):203-210. Disponible en: https://journals.lww.com/jclinrheum/abstract/2009/06000/management_of_patients_with_rheumatoid_arthritis.13.aspx
25. Londono J, Pelaez Ballestas I, Cuervo F, Angarita I, Giraldo R, Serna AM, et al. Prevalence of rheumatic disease in Colombia according to the Colombian Rheumatology Association (COPCORD) strategy. Rev Colomb Reumatol. 2018[citado 03/08/2025];25(4):245-256. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S2444440519300354
26. Fernández Ávila DG, Patino Hernandez D, Kowalskii S, Vargas Caselles A, Sapag AM, Cachafeiro Vilar A, et al. Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. Clin Rheumatol. 2021 [citado 06/05/2025];40(1):377-87. Disponible en: https://link.springer.com/article/10.1007/s10067-020-05555-w
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Danay Legra Cintra, Edilio Silva Velasco, Luis Aníbal Alonso Betancourt
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
